It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Inferring personal intake recommendations of phosphorous and potassium for end-stage renal failure patients by simulating with Bayesian hierarchical multivariate model

Jari Turkia^{1,2*}, Ursula Schwab^{3,4}I, Ville Hautamäki¹I

 School of Computing, University of Eastern Finland, Joensuu, Finland CGI Suomi Oy, Joensuu, Finland School of Medicine, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland Department of Medicine, Endocrinology and Clinical Nutrition, Kuopio University Hospital, Kuopio, Finland

¶These authors contributed equally to this work.

* Corresponding author

E-mail: jari.turkia@cgi.com (JT)

Abstract

Most end-stage renal disease (ESRD) patients face a risk of malnutrition, partly due to dietary restrictions on phosphorous and, in some cases, potassium intake. These restrictions aim to regulate plasma phosphate and potassium concentrations and prevent the adverse effects of hyperphosphatemia or hyperkalemia. However, individual responses to nutrition are known to vary, highlighting the need for personalized recommendations rather than relying solely on general guidelines. In this study, our objective was to develop a Bayesian hierarchical multivariate model that estimates the individual effects of nutrients on plasma concentrations and to present a recommendation algorithm that utilizes this model to infer personalized dietary intakes capable of achieving normal ranges for all considered concentrations. Considering the limited research on the reactions of ESRD patients, we collected dietary intake data and corresponding laboratory analyses from a cohort of 37 patients. The collected data were used to estimate the common hierarchical model, from which personalized models of the patients' diets and individual reactions were extracted. The application of our recommendation algorithm revealed substantial variations in phosphorus and potassium intakes recommended for each patient. These personalized recommendations deviate from the general guidelines, suggesting that a notably richer diet may be proposed for certain patients to mitigate the risk of malnutrition. Furthermore, all the participants underwent either hospital, home, or peritoneal dialysis treatments. We explored the impact of treatment type on nutritional reactions by incorporating it as a nested level in the hierarchical model. Remarkably, this incorporation improved the fit of the nutritional effect model by a notable reduction in the normalized root mean square error (NRMSE) from 0.078 to 0.003. These findings highlight the potential for personalized dietary modifications to optimize nutritional status, enhance patient outcomes, and mitigate the risk of malnutrition in the ESRD population.

Introduction

The majority of end-stage renal disease (ESRD) patients receiving dialysis fail to meet the ² recommended energy and protein intakes, leading to an elevated risk of malnutrition [\[1\]](#page-23-0).

It is made available under a CC-BY 4.0 International license.

Paradoxically, these patients often exceed the recommended levels of phosphorus and saturated ⁴ fats, associated with an increased risk of cardiovascular diseases [\[2\]](#page-23-1). While decreased appetite is $\frac{5}{5}$ a common contributing factor to malnutrition [\[3\]](#page-23-2), the issue may also stem from the general ⁶ nutritional guidelines provided to ESRD patients. Currently, patients with end-stage renal ⁷ disease are provided with general restrictions on dietary phosphorus and, in some cases, potassium intakes to maintain optimal plasma concentrations of potassium, phosphate, and ⁹ albumin. However, an increasing body of knowledge suggests that individual responses to the $\frac{1}{10}$ same nutrition can vary significantly $[4–6]$ $[4–6]$. Given the varying individual responses, it becomes 11 evident that personalized dietary approaches are necessary to achieve target plasma ¹² concentration ranges, rather than relying solely on general guidelines.

Personalized diets are also endorsed for renal failure patients. The National Kidney ¹⁴ Foundation (NKF) in the United States publishes the Kidney Disease Outcomes Quality ¹⁵ Initiative (KDOQI) nutritional guidelines [\[7\]](#page-23-5), which suggest personalized adjustments for dietary $\frac{1}{16}$ phosphorous and potassium intakes to maintain normal ranges of serum phosphate and serum 17 potassium. Implementing these personalized guidelines is a paradigm shift away from fixed ¹⁸ general guidelines [\[8\]](#page-23-6). However, there is a pressing need for a systematic method to derive such $\frac{1}{19}$ personalized guidance. To address this, a statistical approach that models a patient's diet and 20 individual reactions can provide valuable support to clinical nutritionists in justifying $_{21}$ personalized recommendations. ²²

In statistical methodology, *multivariate methods* encompass techniques that simultaneously ₂₃ model multiple response variables, such as several plasma concentrations associated with a given ₂₄ dietary input. These response variables can exhibit direct relations, seeming unrelatedness, or $\frac{25}{25}$ complete independence [\[9\]](#page-23-7). Graphical models, such as directed acyclic graphs (DAGs) or $\frac{26}{5}$ Bayesian networks, can be employed to capture the joint distribution of the response variables by $\frac{27}{27}$ treating the current levels of dietary nutrients and their concentration responses as random 28 variables. These graphical models provide a framework for representing the system and enabling $_{29}$ efficient modeling, particularly in large systems. The efficiency is achieved with the Markov $\frac{30}{20}$ boundaries determining the necessary set of predictor variables, allowing sparse and 31 computationally efficient modeling [\[10\]](#page-23-8). Turkia et al. [\[11\]](#page-23-9) proposed a Bayesian network $\frac{32}{2}$ approach for modeling the personal effects of nutrients using mixed-effect parameterization [\[12\]](#page-24-0). 33 While sparse graphical model offers computational efficiency, it may potentially overlook $_{34}$ valuable information regarding the interconnectedness of concentrations. To address this issue, $\frac{35}{2}$ Bottolo and Banterle et al. [\[13\]](#page-24-1) have provided an efficient Bayesian implementation of *seemingly* ³⁶ *unrelated regressions* (SURs) [\[9\]](#page-23-7) within the context of sparse high-dimensional quantitative trait $\frac{37}{2}$ loci discovery. An efficient implementation of SURs can serve as a useful alternative to Bayesian networks, offering effective modeling of interconnected responses and complementing ³⁹ the benefits of graphical models. $\frac{40}{40}$

To implement personalized nutritional guidance, we developed personalized graphical ⁴¹ models $[10]$ for each of the studied end-stage renal disease patients to simulate their individual 42 reactions to diet modifications. Food intake data and corresponding laboratory analyses were $\frac{43}{43}$ collected from the patients, which were then utilized to construct personalized models of their $\frac{44}{40}$ diets and reactions. Our hypothesis was that the examined concentrations would exhibit a rapid $\frac{45}{15}$ response to variations in nutrient intake, potentially allowing us to statistically estimate the impact of nutrients on concentration levels. While there is limited direct knowledge regarding 47 the relationships between plasma potassium, phosphate, or albumin concentrations, modeling the $\frac{48}{48}$ system using hierarchical seemingly unrelated regression (SUR) allowed for exploratory analysis $\frac{49}{49}$ of potential cross-correlations among these concentrations. Given the limited size of the $\frac{50}{50}$ analyzed data set and the presence of some missing laboratory analyses, the estimated $\frac{51}{51}$ cross-correlations were used to predict the missing values, ensuring the utilization of all available $\frac{1}{2}$ data. It is worth noting that the patients in our study underwent different treatments; either $\frac{1}{5}$ hospital, home, or peritoneal dialysis. To account for this treatment grouping, we included it as a $\frac{54}{10}$ nested level in our hierarchical model of responses. The final personalized models incorporate $\frac{55}{100}$

both the current estimations of the patients' diets and the hierarchically estimated individual ₅₆ responses, thereby representing each patient's unique composition of plasma concentrations. $\frac{57}{20}$

In addition to providing insights into the current composition of concentrations, these $\frac{58}{100}$ personalized graphical models can be utilized to infer targeted nutritional guidance. One of our key contributions is the development of an algorithm that generates personalized diet proposals, ϵ_0 taking into account specific conditions related to selected plasma concentration limits, and $\frac{61}{61}$ providing individualized intake recommendations. Optimal concentration limits vary based on ϵ factors such as age and sex, and our analysis incorporates personalized limits for enhanced ⁶³ accuracy. It is important to note that several diet recommendation options may satisfy the given ϵ_{64} conditions with equal probability, and the selection of the ideal option requires the expertise of a ϵ clinical nutritionist who can consider other personal factors. In our analysis, the objective is to ϵ identify the minimum necessary restrictions on phosphorus and potassium intake for patients $\frac{67}{67}$ with renal failure, aiming to provide dietary recommendations that are as accommodating as $\frac{1}{100}$ possible. And the set of the set o

Our primary objective in this study is to present a Bayesian approach for estimating $\frac{1}{20}$ hierarchical graphical models of personal nutritional behavior, accompanied by an algorithm to $\frac{7}{11}$ infer personalized diet recommendations. We apply these methods to a cohort of patients with $\frac{72}{2}$ end-stage renal disease, highlighting the methods' effectiveness in tailoring phosphorus and $\frac{73}{2}$ potassium intakes to each patient's specific needs. The results of our study reveal considerable $\frac{74}{14}$ variations in recommended intakes, enabling greater dietary flexibility for certain patients while $\frac{1}{75}$ mitigating the risk of malnutrition. By demonstrating the potential of personalized graphical $\frac{1}{76}$ models and individualized diet recommendations, this work contributes to the advancement of $\frac{7}{77}$ personalized nutrition strategies for patients with renal failure.

Dialysis patient data 79

We recruited end-stage renal disease (ESRD) patients for this nutritional study at Kuopio $\frac{80}{20}$ University Hospital dialysis center; 15 women and 22 men participated $(n = 37)$. We considered $\frac{81}{10}$ all patients who were in dialysis treatment and healthy enough to participate. The data collection ⁸² took place from March to September 2018. The ages of the patients ranged from 26 to 81 with $\frac{1}{32}$ an average age of 61. The data consist of food records and laboratory analyses from the same $\frac{84}{94}$ time periods. For each patient, we performed two observations three months apart. On both $\frac{1}{55}$ occasions, the patients were interviewed about their diet in the past 48 hours (48-hour recall ⁸⁶ method), and the nutrients of reported diets were calculated with Aivodiet software (v. 2.0.2.1, $\frac{87}{200}$ Aivo Finland, Turku). The interview dates were selected so that the patients had their regular $\frac{88}{100}$ laboratory tests at the hospital within a week from the interview, either close before or after the laboratory test. The average actualized difference between interviews and laboratory tests was $\frac{90}{2}$ five days, but this delay was over a week for nine patients, and for five of them, as long as three $\frac{91}{21}$ weeks. The laboratory tests always occurred before the dialysis treatments so that the treatment ₉₂ did not affect the test. Table [1](#page-3-0) presents the analyzed nutrients with patients' average levels as $\frac{93}{2}$ well as personal minimums and maximums within the data. Table [2](#page-3-1) displays medications and $_{94}$ other personal details that were used to predict the plasma concentration levels. One notable ⁹⁵ detail is the type of dialysis treatment, which was hospital hemodialysis ($n = 21$), home hemodialysis ($n = 9$), or peritoneal dialysis ($n = 7$). The dialysis type was also included as a predictor for intake recommendations.

Laboratory tests for renal patients included several measurements, from which $\frac{99}{99}$ concentrations of plasma potassium (P-K), fasting plasma phosphorous (fP-Pi), and plasma 100 albumin (P-Alb) were selected as targets of this analysis for exploring the possibility of less 101 restricted phosphorous and potassium intake. The selected predictors were assumed to reflect the 102 composition of these concentrations; all the energy nutrients, vitamin D , minerals, and fluids. 103 Also, the selected medications were known to directly affect the concentrations. Patients fasted before the laboratory tests although there were analyses that did not require fasting. The schema 105

<u>nem preunciors or the model.</u>							
Nutrient	Study avg. (min-max)						
Carbohydrates, E%	43.6 $(27.1 - 63.6)$ E\%						
Fat E%	$38.9(23.4 - 54.1) E\%$						
Monounsaturated Fatty Acids, E%	$14.7(5.6 - 25.1) E\%$						
Polyunsaturated Fatty Acids, E%	$7.1(2.2 - 15.8)$ $E%$						
Protein, E%	$15.1(9.2 - 22.4) E\%$						
Saturated Fatty Acids, E%	$13.7(5.9 - 24.5) E\%$						
Fiber	$17(5 - 42)$ g/d						
Protein, g/kg	0.8 $(0.2 - 2.1)$ g/kg/d						
Energy, kcal/kg	$21.8(5.6 - 58.6)$ kcal/kg						
Calcium	$570(123 - 1741)$ mg/d						
Sodium	2588 (813 - 5487) mg/d						
Phosphorous	$1042(304 - 2184)$ mg/d						
Potassium	2785 (1026 - 5713) mg/d						
Salt	$6560(201 - 13863)$ mg/d						
Water	1804 (601 - 3613) ml/d						
Vitamin D	$8(0 - 31)$ ug/d						

Table 1. Nutrient predictors of the model.

The amount of fatty acids, carbohydrates, and protein is considered as $\%$ of total energy intake (E).

Table 2. Personal details that are used as predictors.

Personal detail	Percentage of patients
Act. D-vit	43%
Blood lipid medication	68%
Diabetes medication	51%
Phosphate binder med.	22%
Renavit	97%
Gender	41% female
Home hemodialysis	24%
Hospital hemodialysis	57%
Peritoneal dialysis	19%

Of these predictors, the type of dialysis treatment (home hemodialysis, hospital hemodialysis, and peritoneal dialysis) is used to form a nested level of hierarchy in the model to estimate their effects on other nutrition and medication.

for data collection is outlined in Fig. [1.](#page-4-0) Patients' targeted normal ranges are reported in Table [3.](#page-4-1) ¹⁰⁶ These ranges adhere to the statements of the hospital laboratory staff who analyzed the 107 concentrations. The numbers provided a normal range for fasting plasma phosphate (fP-Pi) only 108 for healthy persons, but all end-stage renal disease patients (CKD 5D) in this analysis were $_{109}$ undergoing dialysis, and for them, a normal range of 1.13 -1.78 mmol/l is the target, according to 110 KDOQI guidelines $[14]$. The laboratory staff stated that the normal range of plasma albumin 111 (P-Alb) varies depending on the patient's age, and this varying target was considered in our ¹¹² recommendation. Supplementary [S1 Fig](#page-22-0) presents potassium and phosphorous intake levels from $\frac{1}{13}$ the collected food records and their observed effects on these concentrations; the recommended 114 normal ranges are denoted with white areas. General intake recommendations [\[8\]](#page-23-6) for potassium 115 (2500 mg/d) and phosphorous (1000 mg/d) are indicated with black vertical lines. The 2020 $\frac{116}{116}$ update of the KDOQI Clinical Practice Guidelines [\[7\]](#page-23-5) omitted these strict general guides and 117 advised adjusting dietary phosphorus and potassium intakes to maintain normal ranges of serum 118

phosphate and potassium concentrations. 119

Table 3. Personalized normal ranges for plasma concentrations depending on the age of the patient.

Plasma concentration	Normal range	Target group
Plasma potassium (P-K)	$3.4 - 4.7$ mmol/l	Everyone
Fasting plasma phosphate (fP-Pi)	$1.13 - 1.78$ mmol/l	Dialysis patients, CDK 5D
Plasma albumin (P-Alb)	$36-48$ g/l	39 years or younger
Plasma albumin (P-Alb)	$36-45$ g/l	40-69 years old
Plasma albumin (P-Alb)	$34-45$ g/l	70 years and older

Normal plasma potassium and albumin ranges are used according to the hospital laboratory that analyzed the concentrations. All end-stage renal patients in this analysis are in dialysis (CKD 5D) and for they a normal range 1.13-1.78 mmol/l is targeted according to National Kidney Dialysis Outcomes Quality Initiative (KDOQI) guideline. [\[14\]](#page-24-2).

Fig 1. Data collection during the patients' usual treatment routine. The figure is drawn with diagrams.net (v 22.0.6, https://app.diagrams.net).

A research permit for this study was granted by Kuopio University Hospital Research 120 Assistance Center ("KYS Tiedepalvelukeskus" in Finnish) which is an Institutional Review 121 Board of Kuopio University Hospital. The permit waived ethical approval because participants 122 were not subjected to any additional procedures, visits, or tests beyond their usual routine. Instead, only authorized researchers were allowed to handle sensitive and identifying information 124 according to the permit. Patients were given information about the study in writing and orally $\frac{125}{125}$ before starting the study. Before the interviews and data collection, informed written consent 126 was obtained from all participants. The patients had the right to stop their participation in the 127 study at any stage. Participation in the study did not harm the patients and did not affect their treatment. Interviews with the patients took place during their dialysis treatment, and the participants granted permission to utilize their laboratory analyses for the study. Research data 130 were treated confidentially; no individual patient could be identified from the collected data or $\frac{131}{131}$ the results of this study, and thus, no dietary modifications have been done based on this study. 132 The authors of this study cannot identify the participating patients from the collected data or by 133 any other means. Patient IDs in the article figures and tables are only used for patient reference 134 in the results and they cannot be used to identify the study subjects.

Inferring personalized recommendations for nutrient intake

In this section, we present a method used for determining personalized recommendations for $\frac{137}{137}$ nutrient intake. We especially focused on a case where some of the nutrients in a patient's diet were modified while the remaining nutrients maintained their current intake. These recommendations were designed to ensure that the patient's plasma concentrations fall within ¹⁴⁰

It is made available under a CC-BY 4.0 International license.

predefined normal ranges with a desired level of confidence. Achieving this desired confidence ¹⁴¹ level relies on accurate estimates of the patient's current nutrient intake and the effects of 142 nutrients. It is crucial to have a high level of confidence in these estimates before relying on the ¹⁴³ recommendations. To infer personalized nutrient intake recommendations, we began by constructing personal graphical models that replicated the observed concentrations based on the 145 patient's current dietary intake. These personal models were then utilized in simulating the ¹⁴⁶ optimal intake adjustments predicted to maintain normal concentration ranges. A summary of $_{147}$ [v](#page-23-10)ariables, indices, and other notations of the method description is given in Supplementary [S4](#page-23-10) $_{148}$ [Table.](#page-23-10) The contract of the con

Personalized graphical models for plasma concentrations

In our analysis, we constructed a directed graphical model [\[10\]](#page-23-8) G_k for each patient k. These 151 graphical models represented joint conditional distributions over random variables for 152 concentration levels Y_{km} , levels of nutrients in diet X_{kj} , and effects of those nutrients in multiple $\frac{1}{153}$ levels of detail. The graph is illustrated in Fig. [2A](#page-6-0), including the effects of nutrients in the general ($\beta_{k,m}$), dialysis treatment (g_{ljm}), and personal levels (b_{kjm}). Every concentration 155 $m = 1, \ldots, M$ was conditioned with the same $j = 1, \ldots, p$ nutrients and personal treatment type 156 $l = 1, \ldots, L$; hence the edges of the graph are directed towards the concentration levels Y_{km} .

The concentration random variables Y_{kmi} were assumed to follow gamma distribution that 158 allows only positive values and skews to the right, thus allowing occasional values that were $\frac{1}{159}$ α considerably above average [\[15\]](#page-24-3) as follows α 160

$$
Y_{kmi}|\alpha_m, \mu_{kmi} \sim \text{Gamma}\left(\alpha_m, \frac{\alpha_m}{\mu_{kmi}}\right), k = 1, \dots, K, m = 1, \dots, M, i = 1, \dots, n \quad (1)
$$

where α_m was a shape parameter of gamma distribution for concentration m. We used an inverse α_{161} scale parameterization of gamma distribution where its rate parameter was obtained by dividing 162 this shape parameter with an expected value μ_{kmi} for the *i*th observation of patient k. By this 163 formulation, the expected concentration was clearly defined as a linear combination of the ¹⁶⁴ amounts of nutrients and other predictors and their effects with 165

$$
\mu_{kmi} = X_{kj} \beta_{jm} + Z_{kj} g_{ljm} + Z_{kj} b_{kjm}
$$
 (2)

that summed the general effect of a nutrient *j* with the effect variation caused by the dialysis $_{166}$ treatment *l*, and finally, the personal variation within the treatment for patient k. This formed a $_{167}$ nested two-level hierarchical model for repeated personal observations and the effect of treatment that every patient undergoes; either hospital, home, or peritoneal dialysis. Random 169 variable X_{kji} denotes ith observation of predictor j for patient k, and random variables Z_{kji} \cdots denote predictors whose effects were assumed to vary between treatments or patients. In this ¹⁷¹ analysis, all predictors were assumed to vary, and thus X_{kji} and Z_{kji} referred to the same variables, but different sets of predictors could be selected here.

Both parameters of gamma distribution are required to be positive, but we needed to keep the 174 estimated effects of nutrients in an additive scale for direct interpretation. The additive scale can cause problems as it allows also negative values. This was solved by transforming the expected 176 value μ_{kmi} linearly by adding both sides a constant c which was sufficiently large to move the $\frac{177}{177}$ estimation to strictly non-negative values while not affecting the scale of the estimated effects. 178 For parameter α_m , we could apply an exponent link function that enforced non-negative values. $\frac{179}{179}$ It transformed the values to a logarithmic scale, but their direct interpretation was not important 180 for this analysis. The result was a linearly shifted distribution of form

$$
Y_{kmi} + c \vert \exp \alpha_m, \mu_{kmi} + c \sim \text{Gamma}\left(\exp \alpha_m, \frac{\exp \alpha_m}{\mu_{kmi} + c}\right) \tag{3}
$$

where the original distribution Y_{kmi} in Eq. [\(1\)](#page-5-0) was obtained with reverse transformations.

November 10, 2023 6[/26](#page-25-0)

It is made available under a CC-BY 4.0 International license.

Fig 2. Structure of the graphical model with general, treatment, and personal level nutrient effects. A) The hierarchical graphical model for effects of nutrients in general, treatment, and personal levels. B) Information flow of the queried nutrients when conditioned with the current diet, personal effects, and concentration limits. The figure is drawn with diagrams.net (v 22.0.6, https://app.diagrams.net).

Estimating nutritional effects with hierarchical seemingly unrelated regressions

The effects of nutrients were estimated by considering the M different concentration 185 distributions in Eq. [\(1\)](#page-5-0) as seemingly unrelated regressions (SUR) [\[9\]](#page-23-7). In SURs, there are no 186 direct relationships between the regression models, but their hierarchical effects can be dependent on each other. This allowed us to consider all the concentrations simultaneously even 188 though they are not directly related. The estimation was conducted by formulating all expected 189

It is made available under a CC-BY 4.0 International license.

value regressions from Eq. (2) as one univariate matrix: 190

$$
\mu = \mathbf{X}\beta + \mathbf{Z}^{(g)}\mathbf{g} + \mathbf{Z}^{(b)}\mathbf{b},
$$

\n
$$
\mathbf{X} = \mathbf{I}_{M \times M} \otimes \mathbf{X}_{p \times n},
$$

\n
$$
\mathbf{Z}^{(g)} = \mathbf{I}_{M \times M} \otimes \text{diag}(\mathbf{Z}_1^{(g)}, \dots, \mathbf{Z}_L^{(g)}),
$$

\n
$$
\mathbf{Z}^{(b)} = \mathbf{I}_{M \times M} \otimes \text{diag}(\mathbf{Z}_1^{(b)}, \dots, \mathbf{Z}_K^{(b)})
$$
\n(4)

where the model matrix \bf{X} comprises all the predictor variables and was created using a $\frac{1}{191}$ Kronecker product, which is a matrix outer product resulting in a block matrix structure. This 192 pattern follows a block-diagonal arrangement, where the same set of predictors is replicated across all *M* concentration models. Similarly, block matrices $\mathbf{Z}^{(g)}$ and $\mathbf{Z}^{(b)}$ were formed with 194 Kronecker products to repeat, in a block-diagonal pattern, the predictors for treatment and 195 personal effects for each $1, \ldots, L$ treatment and $1, \ldots, K$ person. These matrices contain the same data but were organized differently for selecting the relevant input for each patient and their 197 respective treatment when multiplied by the effect vectors β , **g**, and **b**.

The treatment and personal effect vectors were drawn from multivariate Gaussian 199 distributions, $\mathbf{g} \sim \mathcal{N}(0, \Sigma_g)$ and $\mathbf{b} \sim \mathcal{N}(0, \Sigma_b)$, that were centered to general effects β and had ₂₀₀ variance-covariance matrices Σ_g and Σ_b . The variance-covariance matrices were defined with 201 diagonal matrices $T_g = diag(\sigma_{g_1}, \dots, \sigma_{g_l})$ and $T_b = diag(\sigma_{b_1}, \dots, \sigma_{b_k})$ containing standard 202 deviations for the effects as well as correlation matrices \mathbf{C}_g and \mathbf{C}_b that decompose into triangular Cholesky decomposition matrices L_g and L_b as follows

$$
\Sigma_{g} = \mathbf{T}_{g} \mathbf{C}_{g} \mathbf{T}'_{g} = \mathbf{T}_{g} \mathbf{L}_{g} \mathbf{L}'_{g} \mathbf{T}'_{g},
$$

\n
$$
\Sigma_{b} = \mathbf{T}_{b} \mathbf{C}_{b} \mathbf{T}'_{b} = \mathbf{T}_{b} \mathbf{L}_{b} \mathbf{L}'_{b} \mathbf{T}'_{b}.
$$
\n(5)

This model formulation produces the correlation matrices \mathbf{C}_g and \mathbf{C}_b whose structures contain similar the within-model correlations at diagonal blocks and cross-model correlations at off-diagonal blocks: ²⁰⁷

$$
\mathbf{C} = \begin{bmatrix} \mathbf{D}^{(1)} & \mathbf{C}^{(12)} & \cdots & \mathbf{C}^{(1M)} \\ \mathbf{C}^{(12)'} & \mathbf{D}^{(2)} & \cdots & \mathbf{C}^{(2M)} \\ \vdots & \vdots & \ddots & \vdots \\ \mathbf{C}^{(1M)'} & \mathbf{C}^{(2M)'} & \cdots & \mathbf{D}^{(M)} \end{bmatrix}
$$
(6)

e de la componentación de
En la componentación de la where matrix blocks $\mathbf{D}^{(m)}$, $m = 1, \ldots, M$, denote correlations of effects within a concentration ∞ m and blocks $\mathbf{C}^{(nm)}$ denote effect correlations between concentrations m and $n = 1, \ldots, M$. The 209 correlation matrix blocks are transposed across the diagonal. This system is illustrated as a ²¹⁰ personal graphical model in Fig. [2A](#page-6-0), which depicts these within-model and cross-model ²¹¹ correlations with random variables ρ_{ijmn} of the graphical model.

The estimated variance-covariance matrices provided all the necessary information for 213 predicting the personal effects also for new patients with previously unseen observations. This ₂₁₄ approach was employed in the cross-validation predictions of this study. However, in general, it's 215 important to exercise caution with out-of-sample predictions. The predictions were generated ²¹⁶ using Eq. [\(4\)](#page-7-0) by placing the new observations in data matrices. Personal effect predictions \mathbf{b} 217 follow distribution $\hat{\mathbf{T}}_b \hat{\mathbf{L}}_b \mathbf{z}$ where **z** is a standard normal distribution $\mathcal{N}(\mathbf{0}, \mathbf{I})$ that is scaled with 218 estimated Cholesky decomposition $\hat{\mathbf{L}}_b$ and the standard deviation of the effects $\hat{\mathbf{T}}_b$. In the 219 cross-validation, we utilized the expected values of this predictive distribution as they are the most probable effects to produce the observed concentrations with the given predictors.

Finally, we acknowledged that some nutrients were likely to have collinearly similar effects $\frac{222}{2}$ on concentrations, which could result in inaccurate parameter estimations $[16]$. To decorrelate $\frac{223}{2}$ the independent variables, a QR decomposition [\[17\]](#page-24-5) was used to deconstruct the model matrix of $_{224}$ common effects \bf{X} into an orthogonal matrix \bf{Q} and an upper-triangular matrix \bf{R} . This $_{225}$ deconstruction was further developed into a thin QR decomposition, $\mathbf{X} = \mathbf{Q}^* \mathbf{R}^*$, which is 226

It is made available under a CC-BY 4.0 International license.

equivalent but more computationally efficient, as $\mathbf{Q}^* = \mathbf{Q}\sqrt{n-1}$ and $\mathbf{R}^* = \frac{1}{\sqrt{n-1}}\mathbf{R}$ were scaled 227 down by the number of observations *n*. By estimating parameters $\beta^{*(m)} = \mathbf{R}^* \beta^{(m)}$, significantly ₂₂₈ less correlated common effect coefficients $\beta^{(m)} = \mathbf{R}^{*-1} \beta^{*(m)}$ needed to be calculated as the ²²⁹ matrix \bf{Q} is orthogonal with independent columns. 230

Probabilistic inference with personal generative models

Personalized models were made generative by defining proper prior distributions for all 232 parameters, including the nutrient intakes in each patient's diet. Scholars recognize [\[18\]](#page-24-6) that 233 intake levels follow positive and right-skewed distributions, such as log − normal or gamma ²³⁴ distributions. However, intake distribution is different than estimating the current level of intake ²³⁵ as required in this task. Normal distribution is a better option here, as it captures the variance of $\frac{236}{2}$ the dietary intake observations but reduces the unseen intake levels. We assumed that the mean ₂₃₇ of observations was the expected value of the intake, and the standard deviation of observations ²³⁸ provides uncertainty: 239

$$
X_{kj} \sim \mathcal{N}\left(\hat{\mu}_{kji}, \hat{\sigma}^2_{kji}\right) = \mathcal{N}\left(\overline{X}_{kji}, S_{kji}^2\right), k = 1, \dots, K, j = 1, \dots, J, i = 1, \dots, n \quad (7)
$$

We denote the resulting, fully estimated personalized graph with \hat{G}_k . Personal estimations of $\frac{240}{2}$ the nutritional effects were obtained at the personal, most detailed, level of the hierarchical $_{241}$ model, allowing for fine-grained adjustments that mitigate possible bias inherent in upper levels ₂₄₂ of the model. In this graph, the concentration estimates \hat{Y}_{km} were assumed to settle near their \qquad 243 observed values when using the current nutrient intakes and the estimated effects of nutrients. ²⁴⁴ This allowed analysis of the personal compositions of the concentrations, and in addition, we 245 could also condition the graph for any of its variables. This *probabilistic inference* [\[19\]](#page-24-7) for ²⁴⁶ intake recommendations is illustrated in Fig. [2B](#page-6-0) where the edges connecting to the queried $_{247}$ nutrients were now reversed toward them. We denote this subset of $r = 1, \ldots, R$ nutrients that $\frac{248}{2}$ were queried for recommendations with Q_{kr} and the rest of $j = 1, \ldots, J - R$ nutrients continue ₂₄₉ to be denoted with X_{ki} . They maintained their current personalized estimations while the $\frac{250}{250}$ conditioned nutrient variables were defined with new proposal distributions that allowed all ²⁵¹ possible healthy levels for these nutrients. In this work, we used uniform distributions with ²⁵² nutrient-specific limits, but a more informative distribution could also be used. By denoting this ₂₅₃ personalized graph with modified variables as \hat{G}_{k}^{*} , the conditional probability for the intake $\frac{254}{254}$ recommendation can be formulated as 255

$$
p(Q_{kr}|\hat{G}_{k}^{*}, P(Y_{m}^{l} < Y_{m} < Y_{m}^{u}) > c), r = 1, ..., R, m = 1, ..., M
$$
 (8)

where the queried nutrients Q_{kr} are conditioned with values that cause all plasma concentrations $_{256}$ Y_m to reside within their predefined lower and upper bounds Y_m^l and Y_m^u with probability c.

Algorithm for recommendation sampling ²⁵⁸

Algorithm (1) estimates the conditional recommendation distribution in Eq. (8) by acceptance $\frac{259}{2}$ sampling. In summary, the algorithm samples diet proposals from the previously defined 260 variables Q_{kr} and X_{kj} , and evaluates the probability of how confidently this diet proposal 261 produces plasma concentrations that reside within the requested limits. The distribution of these ₂₆₂ levels of confidence forms the personal recommendation for the queried nutrients Q_{kr} . For clear reporting and systematic comparison between patients, the algorithm returns 2.5% - and 97.5%-quantile values for every recommended nutrient; the example of the full distribution of $\frac{265}{265}$ Eq. [\(8\)](#page-8-0) can be seen in Fig. [3.](#page-10-0) 266

The steps of the Algorithm (1) are explained in detail. To provide transparent reasoning, the 267 algorithm tracks the overall and concentration-specific probabilities of reaching the targets, and ₂₆₈ these are initialized to 0 in Steps (1) and (2). The algorithm iterates extensively on the nutrient $\frac{269}{2}$ medRxiv preprint doi: [https://doi.org/10.1101/2023.08.28.23294523;](https://doi.org/10.1101/2023.08.28.23294523) this version posted November 13, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a CC-BY 4.0 International license.

Fig 3. Detailed Intake Recommendation for Patient 36. The intake recommendation for Patient 36 on the left shows the inferred diet configurations predicted to produce normal ranges of potassium (P-K), phosphate (fP-Pi), and albumin (P-Alb) concentrations. These limits are marked with white areas in the concentration panels on the right. The black point in the middle of the intake plot represents the patient's current potassium and phosphorous intake producing the current concentrations shown with dashed vertical lines. The colored rectangle shows the limits of intake constrained by the correspondingly-colored concentration predictions at the boundaries of the normal ranges. The figure is plotted with ggplot2 package for R language (v 3.4.1, https://ggplot2.tidyverse.org).

random variables and their effects, and their number in the graph is counted in Step (3) . To 270 manage the uncertainty in the potentially wide distributions of these variables, the algorithm 271 uses point estimates in their quantile values. By default, the expected values, in the mean of the ₂₇₂ distributions, are used, but tail quantiles are also useful in sensitivity analysis. The used 273 quantiles are provided by parameters l_x and l_β and they are used to acquire point estimates of z_{74} these random variables in Steps (4) and (5) .

To optimize the sampling, the loop in Step (6) calculates concentration-specific parameters 276 that remain fixed during the sampling. Step (7) calculates the expected values of concentrations 277 without the effect of the queried nutrients. This provides constant baselines of concentration 278 levels $\hat{\mu}_m^{q_0}$ that do not change during the sampling. These constants are used in Steps (8) and (9) 279 to determine the well-defined minimum and maximum limits for the sampled system. The 280

It is made available under a CC-BY 4.0 International license.

expected values $\hat{\mu}_m^{q0}$ are used instead of the required concentration limits if they are lower than λ_{281} the concentration's lower limit or higher than the concentration's upper limit to prevent the 282 sampling from failing.

The main loop in Step (11) draws and evaluates the *S* number of samples from the queried nutrients. Vectors of R coincidental samples are drawn from Q_r in Step (12); a sampling 285 function that is provided with the queried random variables as well as the lower and upper sampling limits from Steps (8) and (9). The queried nutrients Q_r are assumed to follow suitable $_{287}$ proposal distributions for sampling. For actual sampling, we used No-U-Turn sampling ²⁸⁸ (NUTS) [\[21\]](#page-24-8) algorithm to draw the samples from this constrained posterior. This algorithm is $_{289}$ efficient in sampling these multidimensional distributions.

After a diet proposal is sampled, the loop in Step (13) iterates all the concentrations and 291 calculates their expected values in Step (14) as well as the full posterior distribution in Step (15) . The posterior distribution is used in Step (16) to evaluate the confidence level for each diet $\frac{293}{2}$ proposal by assessing the amount of cumulative density between the concentration limits. The $_{294}$ maximum of the reached confidence level is stored for each concentration in Step (17) for $_{295}$ diagnostic purposes.

The algorithm seeks intake proposals that are estimated to take all the concentrations within ₂₉₇ the normal ranges, between Y_m^l and Y_m^u , with the minimum confidence level c; therefore, a 298 minimum of achieved concentrations' confidence level is stored for the current proposal in Step 299 (19) . Step (20) stores also the maximum overall confidence level for diagnostic purposes.

Finally, in Steps $(22)-(25)$, minimum and maximum recommendations are picked for all the 301 queried nutrients. In this implementation, we report 2.5% and 97.5% quantile values of a subset 302 C_r for the queried distributions that have confidence levels in sampled proposals $P(\tilde{q}_{rs}) > c$ for all the concentrations. These quantile values are returned as results in Q_r^{min} and Q_r^{max} . ³⁰⁴

Implementation 305

The probabilistic models for both hierarchical effects of nutrients and personalized ³⁰⁶ recommendations were implemented with the probabilistic programming language *Stan* [\[22\]](#page-24-9) and ³⁰⁷ the estimation of the models was completed through Stan's implementation of No-U-Turn ³⁰⁸ sampling [\[21\]](#page-24-8). Personalized graphical models that use the effect estimations from the hierarchical model were constructed with a custom R-code and iGraph R-package [\[23\]](#page-24-10). These $\frac{310}{2}$ graphs represent random variables as nodes and their connections as edges. The estimated $\frac{311}{211}$ distributions of random variables are stored in the properties of the nodes, which allowed us to 312 fully execute Bayesian inference over the graph. The inference for personalized 313 recommendations through Algorithm (1) was implemented in a custom R-code that filtered the 314 samples that were drawn from the recommendation model. $_{315}$

Data application 316

We applied Algorithm (1) to infer personalized recommendations of phosphorous and potassium 317 intakes for end-stage renal disease patients based on the collected data. Our main results in Fig. 318 [4](#page-12-0) demonstrate considerable differences between patients in the recommended intakes of ³¹⁹ phosphorous and potassium. Some patients could exceed the general recommendations while $\frac{320}{200}$ others should limit intakes of either or both nutrients to levels below the general 321 recommendations. For many patients, though, the required confidence level of personalized 322 recommendations could not be achieved by modifying potassium or phosphorous alone. In $\frac{323}{20}$ particular, the required lower limit of plasma albumin was unreachable for many patients. Detailed results and simulations with personalized models are elaborated next.

It is made available under a CC-BY 4.0 International license.

Fig 4. Personal algorithmic recommendations of potassium and phosphorous intake and the corresponding concentration predictions. The figure illustrates, in the two leftmost panels, personalized recommendations for potassium and phosphorous intake derived from Algorithm [\(1\)](#page-9-0), along with the matching concentration predictions in the rightmost panels. Each row corresponds to a patient with a numeric label and the type of dialysis treatment they are undergoing $(HD =$ hospital hemodialysis, $HHD =$ home hemodialysis, $PD =$ peritoneal dialysis). The colored bars within the intake recommendation utilize blue and red colors to denote whether or not the recommendations surpass the general guidelines of 2500 mg/d for potassium and 1000 mg/d for phosphorous, thus allowing a personally richer intake. Above these bars, numeric values represent the 95% credible interval for each recommendation. These intake recommendations are predicted to produce the concentrations depicted in the right panels. Here, the grey bars represent the estimated concentrations disregarding the impacts of potassium and phosphorous intake (μ_{q0}). When Algorithm [\(1\)](#page-9-0) provides a recommendation with over 90% confidence ($P^{max} > 90\%$), the predicted concentrations within personal limits are highlighted in dark blue. In cases where the recommendation lacks sufficient confidence, the recommendation is excluded, and the entire achievable concentration range is shown with red and blue bars. The red color indicates the concentration whose limits cannot be attained, and for many patients, it is the lower plasma albumin limit. This figure was generated using the ggplot2 package for the R language (v 3.4.1, https://ggplot2.tidyverse.org).

It is made available under a CC-BY 4.0 International license.

Creating personalized models for all patients ³²⁶

Our main interest was to personalize patients' diets to reach the suggested normal ranges of $\frac{327}{227}$ plasma potassium (P-K), fasting plasma phosphorous (fP-Pi), and plasma albumin (P-Alb) in $\frac{328}{2}$ Table [3.](#page-4-1) However, seven of 37 patients had missing plasma albumin measurements. To overcome ₃₂₉ the missing data, we created personalized models for these patients to predict the missing values 330 before the main analysis. The hierarchical model used in Eq. (1) learns typical reactions from $\frac{331}{331}$ patients who have all three concentration measurements available and then generalizes the ³³² reactions for patients who have missing measurement values. In the final data set, we imputed $\frac{333}{2}$ the predicted albumin concentrations for these patients. We assumed that this data imputation 334 provided a minimal bias in data and allowed us to use all of the available measurements.

Table 4. Effects of potassium and phosphorous between different dialysis treatments and between patients within the same treatment.

				Home hemodialysis		Hospital hemodialysis			Peritoneal dialysis		
Nutrient	Conc.	General effect	avg	min	max	avg	min	max	avg	min	max
	P-Alb	-0.19	-2.10	-3.09	-1.87	0.27	-0.41	1.73	0.80	0.10	1.22
Phosphorous		$[-7.16; 6.56]$	$[-10.73; 5.28]$	$[-12.68; 4.94]$	$[-12.44; 7.81]$	$[-5.57; 5.95]$	$-6.77; 6.08]$	$-4.98; 8.63]$	$[-7.31; 8.48]$	$[-8.68; 8.11]$	$[-6.42; 8.81]$
		0.39	0.25	0.15	0.36	0.21	0.10	0.37	0.51	0.45	0.59
Phosphorous	$P-K$	$-2.48:2.31$	$[-1.41:2.02]$	$[-1.57:1.79]$	$[-1.54; 2.84]$	$[-1.20; 1.69]$	$[-1.37; 1.54]$	$[-1.30; 2.61]$	$[-1.42:2.55]$	$[-1.44:2.39]$	$[-1.49; 2.61]$
		0.08	0.15	0.10	0.21	-0.02	-0.09	0.08	0.16	0.05	0.20
Phosphorous	fP-Pi	$[-0.90:1.41]$	$[-1.00; 1.13]$	$[-1.19; 1.23]$	$[-1.14; 1.21]$	$[-0.79:0.79]$	$-0.95; 0.81]$	$-0.63; 0.76]$	$[-0.91; 1.43]$	$[-1.22; 1.43]$	$[-0.90; 1.45]$
		-3.14	-3.89	-5.04	-3.63	-1.06	-1.97	0.34	-0.24	-1.02	0.27
Potassium	P-Alb	$[-15.40; 4.12]$	$[-9.99; 1.30]$	$[-12.20; 0.79]$	$[-9.67; 2.06]$	$[-4.53; 1.96]$	$-8.76; 2.01$	$-3.64; 3.96$	$[-5.53; 5.54]$	$[-7.03; 5.17]$	$[-5.92; 8.05]$
		-0.46	-0.06	-0.32	0.14	0.14	-0.11	0.50	-0.21	-0.51	0.16
Potassium	$P-K$	$-3.35:2.02$	$[-1.48; 1.55]$	$[-2.14:1.32]$	$[-1.57; 1.76]$	$[-0.58; 1.02]$	$-1.40; 1.27]$	$-0.52; 1.64]$	$[-1.66:0.98]$	$[-2.22:1.17]$	$[-1.50; 2.45]$
		0.07	0.00	-0.05	0.04	0.06	0.03	0.09	0.17	0.15	0.21
Potassium	fP-Pi	$-0.88:0.88$	$[-0.72:0.76]$	$[-0.82:0.77]$	$[-0.72:0.78]$	$[-0.34:0.52]$	$-0.51:0.53$	$-0.35:0.56$	$[-0.56:0.97]$	$[-0.68:1.03]$	$[-0.48:1.05]$

The table shows the effects of potassium and phosphorous on concentrations ($m = 1, \ldots, 3$) for analyzed patients ($k =$ 1,..., 37) in all three additive levels of the model. General effects $(\hat{\beta}_{im})$ show the sample mean of the effect that is shown to vary between patients in home hemodialysis, hospital hemodialysis, and peritoneal dialysis. The first column of each dialysis type (avg) shows the typical effect of the treatment $(\hat{\beta}_{im} + \hat{g}_{ljm}, l = 1, ..., 3)$ that can further vary personally. The minimum and maximum of these personal effects $(\hat{\beta}_{im} + \hat{g}_{lim} + \hat{b}_{k}$ are shown within each treatment. For every effect, 90%-credible intervals are shown under the expected value at the posterior mean.

> The main analysis was conducted by first estimating the system of hierarchical nutrient effect ³³⁶ models in Eq. (1) with the three concentration targets and then constructing the personalized $\frac{337}{2}$ graphical models \hat{G}_k for $k = 1, \ldots, 37$ patients. In these personalized models, patients' current asset nutrient intake variables X_{ki} were estimated by using Eq. [\(7\)](#page-8-1). The collected intake data are $\frac{339}{2}$ described in Table [1.](#page-3-0) The table shows also the differing intakes of these nutrients within the study. The input data also included personal factors, such as medication, which are described in $\frac{341}{2}$ Table [2.](#page-3-1) The estimated effects of phosphorous and potassium are provided in Table [4](#page-13-0) at all $_{342}$ hierarchically modeled levels. The effects of all considered nutrients are presented in $\frac{343}{2}$ Supplementary [S3 Table,](#page-23-11) which is arranged in decreasing order of between-treatment variations; 344 with this arrangement, the effect of water on plasma albumin is noticeably different between ₃₄₅ treatments. Table [5](#page-14-0) highlights the strongest effects with high individual variation. The table $_{346}$ shows also the estimated variations of the effects between dialysis treatments ($\hat{\sigma}_g$). It is notable σ_{347} that most varying effects are related to plasma albumin concentration. Further reasoning for the 348 effect predictions is available in Supplementary [S2 Fig](#page-22-1) and [S3 Fig.](#page-22-2) The correlation plots of $\frac{349}{2}$ dialysis treatments and personalized matrices in these figures form a network of associated ³⁵⁰ effects for the sample population. Supplementary [S1 Table](#page-22-3) and [S2 Table](#page-22-4) provide detailed figures 351 of effects that have the highest correlations in levels of treatment and individual patients. ³⁵²

Comparing simulated personalized recommendations

Personalized recommendations were acquired by executing Algorithm [\(1\)](#page-9-0) for all patients 354 $k = 1, \ldots, 37$, and providing a conditioned personalized graphical model \hat{G}_k^* as an input. The sss conditioning was done similarly to that of Fig. $1B$ in which phosphorous and potassium were $\frac{356}{100}$ separated as the queried variables Q_1 and Q_2 , which left the other nutrients, X_j , $j = 1, \ldots, 20$, 357 medRxiv preprint doi: [https://doi.org/10.1101/2023.08.28.23294523;](https://doi.org/10.1101/2023.08.28.23294523) this version posted November 13, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a CC-BY 4.0 International license.

Table 5. Strongest and personally most varying effects of nutrients and medication.

	Expected effect strength								
Effect	General effect			Min. personal		Max. personal	Treatment var.		
Renavit \rightarrow P-Alb		10.04 [-12.1; 24.48]		7.28 [-12.78; 21.69]		12.77 [-7.93; 28.05]		4.66 [0.39; 12.44]	
Potassium \rightarrow P-Alb		-3.14 $[-15.4; 4.12]$		-5.04 $[-12.2; 0.79]$		0.34 [-3.64; 3.96]		4.85 [0.32; 12.99]	
$Salt \rightarrow P-Alb$		1.60 [-8.59; 10.81]		-0.81 [-12.25 ; 8.04]		4.52 [-6.23; 12.73]	6.19	[1.1; 17.17]	
Phosphate binder med. \rightarrow P-Alb		-2.78 [$-9.87; 4.87$]		-4.26 [$-18.77; 8.61$]		0.84 [-10.26; 12.01]		5.74 [0.74; 16.86]	
Fat, $E\% \rightarrow P-Alb$		3.19 [-14.81; 19.59]		1.52 [-17.42; 20.12]		4.14 [-12.29; 19.78]		4.42 [0.77; 10.57]	
Gender \rightarrow P-Alb		1.67 [-5.48; 10.14]		-0.53 [-11.15; 7.42]		4.13 $[-3.8; 11.67]$		6.11 $[0.57; 18.4]$	
SFA , $E\% \rightarrow P-Alb$		-2.58 [-9.85 ; 4.58]		-4.07 [-11.26 ; 3.42]		-1.17 $[-7.44; 4.97]$		5.14 [0.92; 12.4]	
MUFA, $E\% \rightarrow P$ -Alb		1.81 [-6.77; 13.45]		-0.65 [-9.54 ; 8.54]		3.92 [-3.14; 13.42]		5.24 [1.04; 12.71]	
Carbohydrates, $E\% \rightarrow P$ -Alb		1.29 [-14.77; 15.35]		0.16 [-16.99; 15.88]		3.71 [-11.99; 18.43]		5.57 [0.76; 12.7]	
$Hydroxycholecalciferol \rightarrow P-Alb$		1.71 [-6.25; 10.13]		0.54 [-6.56; 8.47]		3.47 [-6.7; 13.94]		5.13 [0.43; 14.33]	
Sodium \rightarrow P-Alb		1.22 [-8.68; 15.01]		-3.28 [-13.36; 7.35]		2.8 [-5.8; 15.93]		6.58 [1.71; 14.24]	
Phosphorous \rightarrow P-Alb		-0.19 [-7.16 ; 6.56]		-3.09 [-12.68 ; 4.94]		1.73 [-4.98; 8.63]		4.25 [0.7; 13.41]	
Energy, kcal/kg \rightarrow P-Alb		1.60 [-11.49; 15.39]		-2.93 [-14.33 ; 8.17]		2.15 [-12.02; 18.26]	5.73	[0.38; 15.28]	
Protein, $g/kg \rightarrow P-Alb$		0.33 [-12.64; 13.11]		-2.72 [-17.16 ; 10.61]		1.62 [-12.93; 15.03]		4.21 [0.54; 10.13]	
Protein, $E\% \rightarrow P-Alb$		0.64 [-7.3; 7.41]		0.88 [-7.16; 8.59]		2.67 [-4.8; 10.24]		3.12 [0.09; 10.49]	
Water \rightarrow P-Alb		-2.04 $[-6.16; 2.97]$		-2.6 $[-8.07; 2.01]$		0.11 [-3.6; 3.77]		8.12 [0.78; 18.33]	
Calcium \rightarrow P-Alb		-0.08 [-10.35 ; 6.03]		-0.32 [-5.36 ; 4.17]		2.6 [-3.21; 11.67]	6.67	[0.5; 19.09]	
PUFA, $E\% \rightarrow P$ -Alb		-0.93 [-6.18 ; 5.86]		-2.42 [-6.01 ; 1.27]		-0.89 [-5.79 ; 4.35]	4.89	[0.65; 11.59]	
Vitamin $D \rightarrow P$ -Alb		1.60 [-1.28; 4.01]		0.11 [-3.45; 3.32]		2.39 [-0.82; 6.41]		4.12 $[0.61; 10.44]$	
$Fiber \rightarrow P-Alb$		1.19 [-5.02; 7.55]		0.7 [-3.35; 4.61]		2.02 [-2.56; 7.51]		4.06 [0.64; 12.82]	

The table presents the 20 effects of nutrients (*j*) on the considered concentrations ($m = 1,...,3$) which are strongest among the studied patients. Here, general effects $(\hat{\beta}_{im})$ represent average responses across the patients studied (k = 1,...,37). Personal effects combine these general effects with variations from treatments (\hat{g}_{ljm} , $\hat{l} = 1, \ldots, 3$) and individual variations within those treatments $(\hat{\beta}_{jm} + \hat{\beta}_{ljm} + \hat{b}_{kjm})$. Additionally, the table displays the estimated effect variation between dialysis treatments ($\hat{\sigma}_g$) and provides 90% credible intervals for all the parameters. All effects are estimated on an additive scale.

It is made available under a CC-BY 4.0 International license.

unmodified. These queried variables were defined with the following proposal distributions $_{358}$

$$
Q_1 \sim \text{Uniform}(0, 5800),
$$

$$
Q_2 \sim \text{Uniform}(0, 2550)
$$
 (9)

where the upper limits of the proposed intakes reflect maximum intakes in the general 359 population. These limits were borrowed from the FinRavinto study [\[24\]](#page-24-11) that studies the intake $\frac{360}{240}$ and nutrition of the Finnish adult population, and in which these limits are the maximum intake 361 for 95% of studied subjects ($n = 565$). For the personalized concentration limits, given with the $\frac{362}{2}$ algorithm parameters Y_{km}^l and Y_{km}^u , we used the normal ranges reported by laboratory staff and 363 KDOQI guidelines [\[14\]](#page-24-2). The plasma albumin upper limit was personalized by the patient's age, ³⁶⁴ as laboratory staff suggested. The exact ranges that were used are reported in Table [3.](#page-4-1) We executed the recommendation sampling with long chains of $S = 10,000$ sample draws for each 366 patient. Besides the means of nutrient level and nutrient effect distributions, the 367 recommendation was executed also with their 5% and 95% quantile values for sensitivity analysis [\[25\]](#page-24-12) of recommendations. The confidence level was also varied with the parameter $\frac{369}{250}$ options $c = 90\%$ and $c = 80\%$.

The algorithm resulted in a recommendation with $P_m^{max} > 90\%$ confidence for 22 of 37 $\frac{371}{2}$ patients, and 17 of those patients could exceed the general recommendations of potassium or 372 phosphorous intake. For the rest of the patients, sufficiently confident recommendations could 373 not be reached. When the 5% and 95% tail quantile values $(l_x \text{ and } l_\beta)$ were used as estimations $\frac{374}{2}$ of current nutrient levels and the nutrient effect, only a few patients received confident $\frac{375}{275}$ recommendations, indicating that distributions for these variables were overly wide and would 376 need further observations to achieve confidence for clinical use. Fig. [4](#page-12-0) illustrates the estimated 377 recommendations for each patient; the first two columns display the recommended intake, and 378 the following three columns offer the predicted concentration levels based on these $\frac{379}{2}$ recommendations. The reported intake recommendations were taken from the 5% and 95% quantile values in the estimated two-dimensional recommendation distributions. This reporting 381 method allowed us to compare otherwise uneven recommendation distributions. It demonstrates that the estimated recommendations range from 1 to 5531 mg/d for potassium and 4 to 2527 $\frac{383}{2}$ mg/d for phosphorous with varying personal configurations. These personalized recommendations are considerably different than the general recommendations of 2500 mg/d for ³⁸⁵ potassium and 1000 mg/d for phosphorous [\[8\]](#page-23-6). 386

Detailed analysis of personalized recommendations 387

From all the personalized recommendations in Fig. [4,](#page-12-0) the estimated two-dimensional ³⁸⁸ distribution for Patient [3](#page-10-0)6 is expanded in Fig. 3 for a closer analysis. The black dot on the intake recommendation plot indicates that the patient's current intake of potassium is approximately ³⁹⁰ 2260 mg/d and phosphorous is approximately 860 mg/d. This intake configuration produced the $\frac{391}{201}$ patient's current plasma concentrations which are indicated by the dashed line at the ³⁹² concentration plots: 3.8 mmol/l plasma potassium, 1.4 mmol/l plasma phosphate, and 40.5 393 plasma albumin. To determine the personal ranges of intake recommendation, the patient's ³⁹⁴ two-dimensional intake recommendation distribution offered simulated intake proposals that $\frac{395}{2}$ were predicted to take all three concentrations to normal ranges; the darkening colors indicate the 396 increasing confidence of the estimation. The rectangle over this distribution defines the area $\frac{397}{97}$ where both intakes produce over 90% confidence in achieving the targeted concentrations. This method for defining regions over uneven recommendation distributions was chosen for systematic reporting and comparison between patients. The rectangle in Fig. [3](#page-10-0) defines the same $\frac{4000}{4000}$ recommendation of 759-2702 mg/d for potassium and 693-1473 mg/d for phosphorous that was provided to Patient 36 in Fig. [4.](#page-12-0) The rectangle's limits have matching colors with the predictive $\frac{402}{402}$ distributions of the concentrations. These four distributions are at the limits of concentration ⁴⁰³ normal ranges and provide constraints for the recommendation.

It is made available under a CC-BY 4.0 International license.

The gray bars in Fig. [4](#page-12-0) indicate the counterfactual expected values of concentrations $\hat{\mu}_m^{q0}$ \qquad where the effects of potassium and phosphorous are totally omitted. This shows any available 406 room in the concentrations to absorb the effects of phosphorous and potassium. For 7 of 22 407 patients who received confident recommendations, the initial concentrations were already over the upper limits, but the linear combinations of proposed intakes and their effects decreased the $\frac{409}{409}$ final concentrations within the normal range. For the rest of the patients, this initial level concentration was already within the normal range or lower than its lower limit. Especially for $_{411}$ plasma albumin, this lower limit was difficult to reach for one-third of the studied patients. ⁴¹²

Evaluation of the personal models 413

Due to the limited number of personal observations, our primary purpose was to model the reactions of the patients in the studied data, but not to make generalizations about the reactions found. We developed several model candidates to explore the mechanisms in data. The models 416 were evaluated with both visual posterior predictive checks [\[26\]](#page-24-13) [\[27\]](#page-24-14) and normalized root mean square errors (NRMSE) that were calculated over all concentration predictions \hat{Y}_{kmi} for K $\qquad \qquad \text{418}}$ patients and M concentrations with

$$
\text{NRMSE} = \frac{\sum_{k=1}^{K} \text{NRMSE}_k}{K}, \text{NRMSE}_k = \frac{\sum_{m=1}^{M} NRMSE_{km}}{M}, \text{NRMSE}_{km} = \frac{\sqrt{\frac{1}{n} \sum_{i=1}^{n} (\hat{Y}_{kmi} - Y_{kmi})^2}}{\bar{Y}_{km}}
$$
(10)

The posterior predictive check in Fig. [5](#page-17-0) compares the distribution of the measured concentrations with the samples drawn from the multivariate model. This check verified that the $_{421}$ model is unbiased as the draws from the concentration model are centered with the measured concentrations. The predictions for phosphate and potassium concentrations have very little $\frac{423}{423}$ variance, but for albumin concentration, the prediction variance is higher. Additionally, we ran simulations with the personal graphical models by drawing samples from current diets and predicting personal concentrations. As no conditioning is done on the diets, the concentrations are expected to settle on their measured values. The differences between the simulated concentrations and the measured concentrations are estimated with the normalized root mean ⁴²⁸ square errors (NRMSE) in Table [6.](#page-17-1) Here we considered an alternative effect model $(mv3)$ cross single level) that omits the dialysis treatment as a separate layer in the hierarchical model but this increased the normalized error from 0.003 to 0.078 . We also considered the concentrations as separate univariate models (separate pk_f fppi), but it increased the overall normalized error to 0.081 indicating the effect of multivariate modeling. All of these models were estimated with a Bayesian modeling framework Stan [\[22\]](#page-24-9) with four chains and 3000 sample draws from each chain with a 1000 sample warm-up period. Model diagnostics confirmed that $_{435}$ there were no divergent transitions during the sampling. The sampling produced an average effective sample size (ESS) of 580 over all model parameters. The chains are also considered mixed as R-hat convergence diagnostic is 1.01 on average. It is recommended that the effective $\frac{438}{438}$ sample size should be well over 100 and R-hat less than 1.05 [\[20\]](#page-24-15) for parameters to be trusted.

Comparison or moder su actures for personal nutrient encets.									
Reaction model	P-K	fP-Pi	P-Alb	average NRMSE					
my3_cross_two_levels	0.003	0.006	0.002	0.003					
my3_cross_two_levels_cv	0.170	0.231	0.063	0.170					
mv3_cross_single_level	0.078	0.233	0.103	0.078					
separate_pk_fppi	0.081	0.175	$\qquad \qquad$	0.081					

Table 6. Comparison of model structures for personal nutrient effects.

The hierarchical model with two levels, personal and dialysis treatment levels, provided the best fit against the studied data as measured with normalized root mean square error (NRMSE). Together with the multivariate modeling of concentrations, it improved the fit in comparison to separately modeled concentrations.

Fig 5. Posterior predictive check (PPC) of the final nutritional effect model. Posterior Predictive Check (PPC) for the final model version: Black lines represent observed concentration levels, while purple lines overlay the predicted concentration levels when all predictor nutrients match observed values. For an unbiased model, the observed and predicted concentrations are expected to be aligned. The figure is plotted with bayesplot package for R language (v 1.10, http://mc-stan.org/bayesplot/).

For external validation, we executed 10-fold cross-validation for the final version 440 (mv3 cross two levels) of the model. In this process, we split the dialysis patient data into ten ⁴⁴¹ folds with three or four of all 37 patients removed from each fold. Personal reactions were $\frac{442}{420}$ predicted for these removed patients while the rest of the data were used for the model 443 estimation. The prediction was made with Eq. (1) by applying the unseen concentration measurements Y_{kmi} and corresponding nutrition data X_{kjm} with the assumption that common 445 effects $(\hat{\beta}_{im})$ and dialysis treatments effects (\hat{g}_{ljm}) remained as previously modeled. Only the 446 personal variations from the dialysis treatment averages were predicted to random variables 447 $\hat{\mathbf{b}}_k = \hat{\mathbf{T}}_b \hat{\mathbf{L}}_b$ **z** where the standard normal distribution **z** ~ Normal(0, **I**) is transformed with the 448 Cholesky decomposition $\hat{\mathbf{L}}_b$ from Eq. [\(5\)](#page-7-1) holding the learned correlations between nutritional $\frac{449}{400}$

It is made available under a CC-BY 4.0 International license.

effects. The related correlation matrix $C_b = L_b L_b'$ is illustrated in Supplementary [S3 Fig](#page-22-2) with $\frac{450}{450}$ the highest correlations highlighted in Supplementary Table [S2 Table.](#page-22-4) Multiplying the 451 distribution with $\hat{\mathbf{T}}_b$ adds the estimated standard deviations of personal effects to it. As a result, $\frac{452}{25}$ the prediction seeks to find the most probable combination of effects $\hat{\mathbf{b}}_k$ from distribution $\frac{453}{2}$ $\hat{\mathbf{T}}_b \hat{\mathbf{L}}_b \mathbf{z}$ given the observations from new patient k. We evaluated also the predicted \mathbf{A}_{54} concentrations with NRMSE and it increased to 0.170 from 0.003 in comparison with the 455 in-sample model. In addition to the smaller amount of data, the increased error can also be 456 explained with unseen patients that react differently than was estimated in the Choslesky matrix $\hat{\mathbf{L}}_b$ of that fold. Supplementary [S5 Fig](#page-22-5) illustrates the cross-validation folds of patients and \qquad compares the modeled and the predicted NRMSE values. ⁴⁵⁹

Finally, we conducted a sensitivity analysis $[25]$ of recommendations by creating personal 460 graphs and recommendations also from the cross-validation predictions. The predicted ⁴⁶¹ recommendations are shown in Supplementary [S4 Fig.](#page-22-6) In comparison to the in-sample $\frac{462}{462}$ recommendations of Fig. [4,](#page-12-0) there are five patients whose predicted reactions did not produce $\frac{463}{463}$ recommendations confident enough, and three patients who could have recommendations with the predicted reactions but not with the in-sample model. All of these changes occurred in recommendations that are very close to the target limits already. The aim of the recommendation ⁴⁶⁶ sensitivity analysis is to ensure that the recommendations are robust and react consistently.

Discussion

The objective of this study was to develop a statistical method for deriving personalized intake $\frac{469}{469}$ recommendations that ensure plasma concentrations remain within or approach the normal ⁴⁷⁰ ranges. We applied this method to infer recommendations for patients with end-stage renal 471 disease (ESRD), a population at higher risk of malnutrition [\[1\]](#page-23-0). We chose to estimate the 472 personalized levels of phosphorous and potassium as their greater intake would allow for a richer 473 diet considering their strict general recommendations. Our decision aligns with the 2020 update $_{474}$ of the KDOQI nutritional guidelines, which advocate for personalized adjustments to maintain ⁴⁷⁵ normal ranges of plasma phosphate and potassium [\[7\]](#page-23-5). By applying our method, we provided a 476 statistically justified inference of personalized dietary intake likely to result in normal plasma 477 concentrations. Consequently, we observed considerable variations in the recommended dietary ⁴⁷⁸ intake of phosphate and potassium for each patient. 479

Limitations and reliability of the study ⁴⁸⁰

The data collected for this study had certain limitations, including a small sample size of patients 481 $(n = 37)$ and a limited number of observations per patient. Each patient underwent only two 482 dietary interviews and corresponding laboratory analyses of concentrations. The scarcity of data 483 can be attributed to the fragility of renal patients undergoing dialysis, which poses challenges in ⁴⁸⁴ conducting extensive studies involving this population. The main motivation of this study was to $\frac{485}{485}$ address the malnutrition-induced weakness experienced by these patients, but the subject is complicated to investigate, and thus literature on the nutritional reactions of renal disease 487 patients is also limited. Given the small amount of data, it is not recommended to generalize the ⁴⁸⁸ findings of this study beyond the studied patients without further research.

However, we showed in Table [6](#page-17-1) that including the patients' grouping in different types of $_{490}$ dialysis treatments improved the personal models' fit considerably, and as a result, the ⁴⁹¹ multivariate model repeats the observed concentrations without bias in Fig. [5.](#page-17-0) This makes the $\frac{492}{492}$ expected values of nutritional reactions solid to conclude that there exist personal differences within this patient population, and there is a need for personal inference of nutrition intake. Another source of uncertainty in the inference is the estimation of patients' current intake levels. 495 In this partial recommendation, only levels of phosphate and potassium were conditioned, while $\frac{496}{4}$ the rest of the diet remained unmodified. For accurate recommendations, the contribution of the

unmodified diet should be accurately estimated, and Algorithm (1) brings these contributions out $_{498}$ with parameters $\hat{\mu}_m^{q0}$ to support the reasoning.

A major modeling decision was to choose whether the relations between the concentrations $_{500}$ should be estimated, or if they should be considered independently. The latter provides a sparse $\frac{501}{201}$ and computationally efficient structure in a Bayesian network $[28]$, but we have demonstrated $\frac{502}{2}$ that with this small amount of data, also multivariate computation can be accomplished. We $\frac{503}{503}$ conclude that if there exist cross-model correlations, then a multi-target recommendation requires a multivariate model of the reactions. In this analysis, sparse cross-model correlations ₅₀₅ are proven to exist, and including them enhanced the predictions as was seen in the decrease of normalized root mean square error.

Application of the inference method 508

Our goal was to develop a recommendation method that enables practitioners to transparently ⁵⁰⁹ follow the inference process. By estimating the nutrient components contributing to plasma concentrations, our method allows for inference regarding the hypothetical scenario where the $\frac{511}{2}$ intake of phosphorus and potassium is completely omitted. These concentration baseline 512 parameters, denoted as $\hat{\mu}_m^{q_0}$, serve as fixed starting points in the recommendation algorithm. Based on these baselines, the recommendation method offers three options for proceeding. In 514 the first two options, the estimated baselines are either above or below the normal ranges of $\frac{515}{515}$ concentrations. If simulating intakes of phosphorus and potassium alone fails to reach the ⁵¹⁶ normal ranges, the recommendation is deemed unsuccessful. In the third option, if the baselines $\frac{517}{211}$ already fall within the normal range, it is still necessary to accumulate a sufficient probability $\frac{1}{518}$ mass from the predictive distributions of concentrations within the normal ranges to provide a 519 confident recommendation. As the model gains more information about individual reactions, the 520 predictive distributions are expected to become more tightly concentrated, with their expected values approaching the limits of the normal ranges. Consequently, the method can generate $\frac{522}{222}$ confident recommendations for more permissive diets. This concept is illustrated in Fig. 3 , $\frac{523}{2}$ where the predictive distributions of plasma potassium push against the boundaries of the normal 524 ranges, thus constraining the corresponding intake recommendation. The breadth of these $\frac{525}{256}$ distributions signifies the uncertainty stemming from personalized estimations of diet and its $\frac{526}{200}$ effects. For reporting purposes, the recommendations presented in this study utilize the expected $\frac{527}{222}$ values of the predicted concentration distributions.

In addition to facilitating comparisons between patients, our method also supports $_{529}$ personalized nutritional guidance, as exemplified in Fig. [3.](#page-10-0) This figure depicts the current ⁵³⁰ phosphorus and potassium intakes of Patient 36, along with the corresponding concentration $_{531}$ levels. Despite all considered plasma concentrations falling within the normal ranges with the given intake levels, it is crucial to determine the boundaries of intake necessary to maintain $\frac{533}{2}$ concentrations within those ranges. Based on the personal model developed for Patient 36 , $\frac{534}{2}$ Algorithm (1) generates a recommendation for potassium intake ranging between 759 and 2702 $\frac{1}{535}$ mg/d, and for phosphorus intake ranging between 693 and 1473 mg/d. Notably, the expected $\frac{536}{5}$ concentration values for a simulated diet without potassium and phosphorus intake already fall $\frac{537}{2}$ within the normal ranges, along with substantial portions of the concentration predictive $\frac{538}{538}$ distributions. By comparing the corresponding colors of the intake recommendation limits and ⁵³⁹ the predictive distributions of concentrations in Fig. [3,](#page-10-0) we can deduce certain relationships. The $_{540}$ concentration of plasma potassium $(P-K)$ increases as potassium intake increases, while it also $_{541}$ becomes evident that plasma potassium concentration increases with decreasing phosphorus $_{542}$ intake. On the other hand, phosphorus intake has minimal impact on plasma phosphate $\frac{543}{543}$ concentration. However, a decrease in phosphorus intake results in an increase in plasma ⁵⁴⁴ albumin concentration (P-Alb). Together, these reactions define the lower limit of the $\frac{545}{545}$ phosphorus intake recommendation and the upper limit of the potassium intake recommendation. ⁵⁴⁶ As phosphorus intake increases and potassium intake decreases, the lower limits of the normal $_{547}$

It is made available under a CC-BY 4.0 International license.

ranges for potassium and albumin concentrations are first met. For many patients, the recommendation is constrained by the upper limit of fasting plasma phosphate and the lower $\frac{549}{549}$ limit of plasma albumin. In clinical practice, making choices among different diet options that $\frac{550}{500}$ yield computationally identical concentrations requires nutritional expertise and may vary between patients, depending on individual factors. 552

Considerations on the personal effects of nutrients

In the partial recommendation presented in this study, only the levels of phosphate and potassium $_{554}$ were specifically adjusted, while the remainder of the diet was left unmodified. The factors taken 555 into account for personalized recommendations were the estimated nutritional reactions and the $\frac{556}{2}$ composition of the current diet. The literature on the nutritional reactions of renal disease 557 patients is scarce, but our hierarchical reaction model indicated that incorporating the type of $\frac{558}{558}$ dialysis treatment as a nested level of grouping improved the accuracy of the model. While there $\frac{559}{100}$ are differences in the average reactions among patients receiving different dialysis treatments, $\frac{560}{600}$ individual variations in reactions were also substantial for many factors. Notably, the average effect of water intake on plasma albumin showed the greatest variation among the different ₅₆₂ dialysis treatments. Patients undergoing hospital hemodialysis exhibited weaker reactions ⁵⁶³ compared to those undergoing home or peritoneal dialysis. This difference is likely attributed to $_{564}$ the less frequent occurrence of hospital hemodialysis and the treatment guidance in hospital ₅₆₅ settings that restricts fluid and sodium intake [\[7\]](#page-23-5) [\[14\]](#page-24-2). Our results also revealed weaker sodium $_{566}$ reactions in hospital dialysis. $\frac{567}{200}$

It is worth noting that the nutrient effects on plasma albumin concentration exhibited the $\frac{568}{568}$ greatest variability among patients. However, it is important to interpret this result cautiously, as $\frac{569}{100}$ the posterior predictive check in Fig. [5](#page-17-0) indicated a high variance in the model predictions for $\frac{570}{570}$ plasma albumin concentration, despite the predictions being unbiased. We attribute this high $\frac{571}{571}$ variance to the fact that plasma albumin concentration cannot be fully predicted based on the $\frac{572}{572}$ nutrient intake. In fact, it is reported that plasma albumin and prealbumin concentrations should $_{573}$ not be relied upon as exclusive nutritional markers [\[29\]](#page-25-2). These concentrations may decrease in 574 the presence of inflammation, regardless of the underlying nutritional status. Upon treating the $\frac{575}{200}$ malnutrition, the inflammation may subside, leading to an increase in albumin concentration. $\frac{576}{100}$ Polyunsaturated fatty acids (PUFA) are known to have inflammatory properties [\[30\]](#page-25-3) and can aid 577 in the recovery process. However, the specific effect of PUFA on albumin concentration has $\frac{578}{578}$ been shown to vary among patients. Thus, the composition of albumin concentration is more $\frac{579}{200}$ intricate compared to the other considered concentrations. Lastly, the intakes of both phosphorus and potassium also exhibit individually varying effects on all the concentrations, as presented in $\frac{581}{581}$ Table [4.](#page-13-0) Addressing this variation is our primary contribution and is reflected in the resulting $\frac{582}{582}$ personalized recommendations. $\frac{583}{200}$

Future work 584

Currently, Algorithm (1) requires that all concentration targets must be fully reached before $\frac{585}{585}$ providing a recommendation. However, it is possible to allow patients to partially reach the $\frac{586}{586}$ targets, which would necessitate defining an order of importance among the concentrations. In $\frac{587}{200}$ such a scenario, achieving the most important concentration would be required, while the less $_{588}$ important concentrations would need to be reached to the greatest extent possible. In our future $\frac{589}{2}$ work, we intend to personalize the intake recommendations for all nutrients or as many as practically feasible. We have observed that modifications in phosphorus and potassium levels $_{591}$ alone were not sufficient for all patients. However, this poses computationally a more $_{592}$ challenging problem, as there will be numerous dimensions to consider in the recommendation $\frac{593}{2}$ distribution beyond these two nutrients. Currently, the recommendation algorithm provides 594 parameters that can be used to track the inference process. However, collecting and interpreting 595 the relevant parameters may be a tedious task. Therefore, in our future work, we aim to enhance $\frac{596}{2}$

It is made available under a CC-BY 4.0 International license.

the interpretability of the recommendations by incorporating an algorithmic explanation $_{597}$ alongside them. This will help users better understand the reasoning behind the personalized ₅₉₈ recommendations and facilitate their implementation in clinical practice.

Conclusion

In conclusion, this work shows that end-stage renal disease (ESRD) patients are unique in many ϵ_{01} ways. These patients exhibit varying responses to nutrients, follow diverse dietary patterns, and 602 even possess distinct targeted normal ranges for plasma concentrations. The task of providing $\frac{603}{603}$ well-grounded intake recommendations becomes challenging without the aid of computational tools. Fortunately, probabilistic graphical models have proven to be a viable approach for ⁶⁰⁵ personalized modeling. These models offer flexibility in diet inference, while the Bayesian 606 framework empowers practitioners to effectively manage uncertainty in estimations. Moreover, $\frac{607}{607}$ the inclusion of a hierarchical model parameterization enables the graphical models to provide $\frac{608}{608}$ recommendations that can be tailored to more granular levels, including population, treatment, $\frac{609}{2}$ and individual preferences. Our contributions can be summarized in the following: $\frac{610}{610}$

- This study provides evidence that there exist considerable and quantifiable differences in $\frac{611}{611}$ how renal patients' plasma concentrations react to the same nutrition.
- As also the patients' diets differ, personally different phosphorous and potassium intakes 613 are needed for maintaining normal plasma phosphate and potassium concentrations. ⁶¹⁴
- Bayesian inference provides a systematic method for personal phosphorous and potassium 615 recommendations and could support clinical nutritionists in providing personalized ⁶¹⁶ guidance. **617** and 617 and 61

Data availability

All the code and data for fully reproducing this analysis are publicly available in Github $\frac{619}{619}$ repository: https://github.com/turkiaj/inferring-personal-recommendations-for-renal-patients. ⁶²⁰ A minimal underlying data set is provided also in Supporting Information files.

Although the patients cannot be directly identified from the data, the examination dates were 622 removed from the shared data to ensure privacy. For the sake of this analysis, only the number of $\epsilon_{0.83}$ days between the interview and laboratory test is relevant, and only this information is left in the 624 $data.$

References ⁶²⁶

Author information 627

Ursula Schwab and Ville Hautamäki contributed equally.

Author contributions ⁶²⁹

JT designed the model and executed the data analysis, VH contributed to model design and $\frac{1}{630}$ statistical verification of the model, and US provided the nutritional data and nutritional $\frac{631}{631}$ interpretation of the results. All authors critically reviewed the manuscript and approved its final $\frac{632}{632}$ version. The corresponding author is responsible for submitting on behalf of all authors of the 633 paper. The contract of the con medRxiv preprint doi: [https://doi.org/10.1101/2023.08.28.23294523;](https://doi.org/10.1101/2023.08.28.23294523) this version posted November 13, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a CC-BY 4.0 International license.

It is made available under a CC-BY 4.0 International license.

S3 Table. All the estimated nutrition effects in general, dialysis treatment and personal 671 **levels.** Nutrition effect magnitudes from nutrients and other modeled features $(j = 1, \ldots, 22)$ to σ blood concentrations $(i = 1, \ldots, 3)$ for analyzed patients $(p = 1, \ldots, 37)$ in all three additive $\qquad \qquad \text{673}$ levels of the model. General effects $(\hat{\beta}_{ij})$ are shown to vary between patients in home hemodialysis, hospital hemodialysis, and peritoneal dialysis. The first column of each dialysis 675 type (avg) shows the typical effect of the treatment $(\hat{\beta}_{ij} + \hat{\beta}_{ijk}, k = 1, ..., 3)$ that can further $\qquad \circ \circ$ vary personally. Minimum and maximum of these personal effects are shown within each 677 treatment $(\hat{\beta}_{ij} + \hat{g}_{ijk} + \hat{b}_{ijp})$. The table is sorted in decreasing order of between-treatment ϵ_{gs} variation $(\hat{\sigma}_g)$ and all the estimates include their 90%-credible intervals.

S4 Table. Summary of notation for Method section. ⁶⁸⁰

References

- 1. Kalantar-Zadeh K, Tortorici AR, Chen JLT, Kamgar M, Lau WL, Moradi H, et al. Dietary restrictions in dialysis patients: is there anything left to eat? Semin Dial. 2015;28(2):159–168.
- 2. Jankowski J, Floege J, Fliser D, Bohm M, Marx N. Cardiovascular disease in chronic ¨ kidney disease: Pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–1172.
- 3. Yassibas E, Sahin G, Sanlier N. Dietary intakes and some biochemical markers in hemodialysis patients. Journal of Human Sciences. 2016;13(1):1355–1366.
- 4. Cecil JE, Barton KL. Inter-individual differences in the nutrition response: from research to recommendations. Proceedings of the Nutrition Society. 2020;79(2):171–173. doi:10.1017/S0029665119001198.
- 5. Chaudhary N, Kumar V, Sangwan P, Pant NC, Saxena A, Joshi S, et al. Personalized Nutrition and -Omics. Comprehensive Foodomics. 2021; p. 495–507. doi:10.1016/B978-0-08-100596-5.22880-1.
- 6. Boorsma A, van Someren E, de Hoogh I, Hogenelst K, van Erk M, Wopereis S, et al. Systems biology of personalized nutrition. Nutrition Reviews. 2017;75(8):579–599. doi:10.1093/nutrit/nux029.
- 7. Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan W, et al. KDOQI Clinical Practice Guideline for nutrition in CKD: 2020 update. Am J Kidney Dis. 2020;76(3 Suppl 1):S1–S107.
- 8. Kopple JD. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. American Journal of Kidney Diseases. 2001;37(1, Supplement 2):S66–S70. doi:https://doi.org/10.1053/ajkd.2001.20748.
- 9. Mehtatalo L, Lappi J. Biometry for Forestry and Environmental Data: With Examples in R (1st ed.). Chapman and Hall/CRC; 2020. Available from: <https://doi.org/10.1201/9780429173462>.
- 10. Koller D, Friedman N. Probabilistic Graphical Models: Principles and Techniques - Adaptive Computation and Machine Learning. The MIT Press; 2009.
- 11. Turkia J, Mehtätalo L, Schwab U, Hautamäki V. Mixed-effect Bayesian network reveals personal effects of nutrition. Scientific Reports. 2021;11(1):12016. doi:10.1038/s41598-021-91437-3.

It is made available under a CC-BY 4.0 International license.

- 12. Bae H, Monti S, Montano M, Steinberg MH, Perls TT, Sebastiani P. Learning Bayesian Networks from Correlated Data. Scientific Reports. 2016;6(1):25156. doi:10.1038/srep25156.
- 13. Bottolo L, Banterle M, Richardson S, Ala-Korpela M, Jarvelin MR, Lewin A. A ¨ computationally efficient Bayesian seemingly unrelated regressions model for high-dimensional quantitative trait loci discovery. Journal of the Royal Statistical Society: Series C (Applied Statistics). 2021;70(4):886–908. doi:https://doi.org/10.1111/rssc.12490.
- 14. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–201.
- 15. Limpert E, Stahel WA. Problems with Using the Normal Distribution – and Ways to Improve Quality and Efficiency of Data Analysis. PLOS ONE. 2011;6(7):1–8. doi:10.1371/journal.pone.0021403.
- 16. Bishop CM. Pattern Recognition and Machine Learning (Information Science and Statistics). Secaucus, NJ, USA: Springer-Verlag New York, Inc.; 2006.
- 17. Strang G. Linear Algebra and Learning from Data. Wellesley-Cambridge Press; 2019. Available from: https://books.google.fi/books?id=L0Y_wQEACAAJ.
- 18. Carriquiry AL. Estimation of Usual Intake Distributions of Nutrients and Foods. The Journal of Nutrition. 2003;133(2):601S–608S. doi:10.1093/jn/133.2.601S.
- 19. Pearl J. Probabilistic Reasoning in Intelligent Systems: Networks of Plausible Inference. Morgan Kaufmann series in representation and reasoning. Morgan Kaufmann Publishers; 1988. Available from: <https://books.google.fi/books?id=Db4eHj9ZL4UC>.
- 20. Aki Vehtari and Andrew Gelman and Daniel Simpson and Bob Carpenter and Paul-Christian Bürkner Rank-Normalization, Folding, and Localization: An Improved R for Assessing Convergence of MCMC (with Discussion) Bayesian Anal. 2021;16(2):667–718.
- 21. Homan MD, Gelman A. The No-U-Turn Sampler: Adaptively Setting Path Lengths in Hamiltonian Monte Carlo. J Mach Learn Res. 2014;15(1):1593–1623.
- 22. Carpenter B, Gelman A, Hoffman M, Lee D, Goodrich B, Betancourt M, et al. Stan: A Probabilistic Programming Language. Journal of Statistical Software, Articles. 2017;76(1):1–32. doi:10.18637/jss.v076.i01.
- 23. Csardi G, Nepusz T. The igraph software package for complex network research. InterJournal. 2006;Complex Systems:1695.
- 24. Valsta L, Kaartinen N, Tapanainen H, Männistö S, (eds.) KS. Ravitsemus Suomessa – FinRavinto 2017 -tutkimus [Nutrition in Finland – The National FinDiet 2017 Survey]. FinRavinto2017. 2018; p. 239.
- 25. A S, M R, T A, F C, J C, D G, et al. Global Sensitivity Analysis: The Primer. Chichester (England): Wiley; 2008. Available from: <http://eu.wiley.com/WileyCDA/WileyTitle/productCd-0470059974.html>.
- 26. Gabry J, Simpson D, Vehtari A, Betancourt M, Gelman A. Visualization in Bayesian workflow. Journal of the Royal Statistical Society Series A. 2019;182(2):389–402. doi:10.1111/rssa.12378.
- 27. Gelman A, Carlin J, Stern H, Dunson D, Vehtari A, Rubin D. Bayesian Data Analysis. 3rd ed. CRC Press; 2013.

medRxiv preprint doi: [https://doi.org/10.1101/2023.08.28.23294523;](https://doi.org/10.1101/2023.08.28.23294523) this version posted November 13, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

- 28. Nagarajan R, Scutari M. Bayesian Networks in R with Applications in Systems Biology. New York: Springer; 2013.
- 29. Evans DC, Corkins MR, Malone A, Miller S, Mogensen KM, Guenter P, et al. The use of visceral proteins as nutrition markers: An ASPEN position paper. Nutr Clin Pract. 2021;36(1):22–28.
- 30. Marion-Letellier R, Savoye G, Ghosh S. Polyunsaturated fatty acids and inflammation. IUBMB Life. 2015;67(9):659–667.